The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Open accessAbstract
BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a least-squares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months. (Funded by Alnylam Pharmaceuticals and the Medicines Company; ClinicalTrials.gov number, NCT02314442 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran is the first siRNA approved by both US FDA and EMA for the treatment of hypercholesterolemia; the subcutaneous injection of a lipid nanoparticle formulation of the drug, which specifically binds hepatocyte asialoglycoprotein receptors, displays high potency in lowering liver PCSK9 and plasma LDL-C levels [161,162].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single subcutaneous injection of trivalent GalNAc-conjugated siRNA can achieve efficacy for >12 months22, 2324.”
From A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“However, a fibrate-induced increase in homocysteine may blunt elevation of both HDL-C and ApoA1 levels, and this effect may contribute to the smaller than estimated benefits of fenofibrate in CV outcome parameters [322].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [322]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationTabernero, J. M., Shapiro, G. I., LoRusso, P. M., Cervantes, A. M. R., Schwartz, G. K., Weiss, G. J., Paz-Ares, L. G., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 717
Self-citationEffect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 644
Self-citationZhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–775 of 775
Diniz, E. T., Cardoso, A. C. S., & Bandeira, F. A. F. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_44
Jebari‐Benslaiman, S., Galicia-García, U., Larrea, A., Uribe, K. B., Martín, C., & Benito‐Vicente, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00033-x
Li, D. ‘. (2018) · Springer eBooks · doi:10.1007/978-3-319-68379-9_7
小倉, 正., & 斯波真理子 (2018) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.27.0_64
Ogura, M. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.10.014
Targeted delivery of therapeutic oligonucleotides in pancreatic cancer
Iris, Y. (2022) · Journal of Biology and Medicine · doi:10.17352/jbm.000028
Research Progress of Inclisiran
王, 玉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.1281061
Inclisiran, ARN interferente pequeño: un nuevo enfoque para el tratamiento del colesterol
Fragozo-Ramos, M. C., Gómez-Sierra, V., Gómez-Galvis, L. V., Campo, R., Santos, R. D., & Román-Gonzaléz, A. (2022) · Revista Colombiana de Cardiología · doi:10.24875/rccar.21000150
Inclisiran — lipid-lowering drug using RNA therapy. Hypolipidemic potential
Sumarokov, A. M. (2022) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20221704132
Bambauer, R., Schiel, R., & Salgado, O. S. (2023) · British journal of healthcare and medical research · doi:10.14738/bjhmr.102.14266
Brandts, J., & Ray, K. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00021-2
Radchik, E., Davis, L. L., & Blyler, C. A. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.05.006
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Haverich, A., & Boyle, E. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31766-8_2
Lang anhaltende LDL-C-Senkung mit nur zwei Applikationen pro Jahr
Novartis Pharma Schweiz, A. G. (2023) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2023.09459
Diminution de longue durée du LDL-C avec seulement deux administrations par an
Novartis Pharma Schweiz, A. G. (2023) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2023.09459
Effiziente LDL-Cholesterinsenkung auf RNA-Ebene [2]
Novartis Pharma, A. G. (2023) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2023.09482
Effiziente LDL-Cholesterinsenkung auf RNA-Ebene [2]
Novartis Pharma, A. G. (2023) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2023.09482
The future is now: promising therapies
Ruiz, Á. J., Campo, R., Román-Gonzaléz, A., & Santos, R. D. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000215
(2023) · Journal of Clinical & Experimental Immunology · doi:10.33140/jcei.08.03.04
Therapies in Disorders of Lipid Metabolism and Obesity
Akuffo Quarde, M. D. (2023) · Wiley eBooks · doi:10.1002/9781119863564.ch7
Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL
Matteucci, S., Pravatà, V., Esposito, F. M., Pirillo, A., Grigore, L., & Catapano, A. L. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i1.59
Principles of novel cellular and molecular cardiovascular therapeutics
Furtado, M., Ribeiro, M., Martins, S., Carvalho, T., & Carmo‐Fonseca, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822951-4.00042-4
Women in Experimental Pharmacology and Drug Discovery Pharmacology 2023
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5208-7
Percorso diagnostico e terapeutico della dislipidemia nel paziente ad alto rischio cardiovascolare
Venturini, E., Casolo, G., Comeglio, M., Fattirolli, F., Limbruno, U., Orso, F., Pino, B. D., Berteotti, M., Angelotti, P., Marcucci, R., et al. (2024) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.23.05196-3
Reviews in Cardiovascular Pharmacology: 2023
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-6052-5
Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS databasePreprint
Deng, C., Xu, Y., Pan, Y., Wu, T., Fan, C., Jiang, Z., Lv, M., BingxinBai, Du, Z., Wang, Z., et al. (2025) · doi:10.22541/au.174127529.93210053/v1
Loss of Zdhhc8 induced apoptosis in Drosophila
Wang, M. (2025) · BIO Web of Conferences · doi:10.1051/bioconf/202517401020
Research Progress of Lipoprotein(a) in the Diagnosis and Treatment of Coronary Heart Disease
梁, 元. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1572080
Treatment of dyslipidemia: PCSK-9 in focus
Lukač, S. S., Popović, L., Rasulić, I., Petakov, A., Bogdanović, J. M., Mitrović, M., Krstic, M., & Lalic, K. S. (2025) · Medicinska istrazivanja · doi:10.5937/medi0-55356
3) SiRNA Drug Inclisiran for Lowering Serum LDL-cholesterol Levels
Yamashita, S. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1572
Zhao, X., Li, X., Zhang, S., Song, W., Fang, H., & Jin, K. (2025) · Precision Chemistry · doi:10.1021/prechem.5c00107
High-resolution RNA knockdown profiles of small RNA and Cas13 systemsPreprint
Kong, J., Leung, S. S. K., Wu, G., Lau, C. F., Mok, B. W.-Y., Weng, M., Jauch, R., Chen, H., & Kwon, S. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.17.688664
Liu, D., Liu, J., Mao, W., Li, X., Hu, B., Zhang, L., & Hu, J. Y. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001778
刘, 美. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113273
Forsyth, F., & Devaux, Y. (2026) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvag008
Effects of Inclisiran on Systemic Inflammatory Biomarkers: A Systematic Review
Warham, W., Padri, N. F. A., Zeth, W., Ahmad, A. I., Aksi, A. M., & Ara, A. A. S. A. (2026) · International Journal of Health and Pharmaceutical (IJHP) · doi:10.51601/ijhp.v6i1.515
Familial hypercholesterolemia: diagnosis, genetic aspects, and current treatment approaches
Bazhin, M. A., Свеклина, Т. С., Krutikova, A. A., Strelkov, D. A., & Bessonov, E. Y. (2026) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma682901
Nusantara, A. C. P., Rapsanjani, A. D., Handirosiyanto, I., Mandiricha, T., & Gaffar, A. S. (2026) · International Journal of the Cardiovascular Academy · doi:10.4274/ijca.2026.53315
Le rôle du récepteur aux LDL et de PCSK9 dans le diabète de type 2
Ramin‐Mangata, S. (2020) · theses.fr (ABES) · doi:10.70675/26622ba5zb0fcz4d30za6e6z5c95a0b5a33d
Mécanisme de régulation de l’activité du microARN miR-16 dans le mélanome uvéal
Quéméner, A. M. (2020) · theses.fr (ABES) · doi:10.70675/b6a2cadfz77d7z48b6zb573zaab26d81396e
Rôle des cellules de Kupffer dans l'homéostasie du cholestérol
Fima, R. (2022) · theses.fr (ABES) · doi:10.70675/57f4dd66z9dc1z45c7z8619z4ddb93538c40
Wang, H., Zhang, X., Liang, Y., Zeng, Z., Bi, L., Yang, Y., Pan, J., Dai, G., Wu, G., & Fan, W. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.04.012
The role of PCSK9 in cancer risk: Population-level evidence and mechanistic insights
Liu, H., Zhou, T., Wang, L., Liu, F., & Gu, D. (2026) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000141
The role of mitochondrial dynamics in metabolic dysfunction–associated steatotic liver disease
Yang, N., & Hao, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1804561
Freijo, M. D. M., Cardona, P., Castellanos, M., de Torres-Chacón, R., Gil-Núñez, A., Guillán, M., Martínez‐Sánchez, P., Palacio-Portilla, E. J., Purroy, F., Segura, T., et al. (2026) · Neurología · doi:10.1016/j.nrl.2026.502076
Freijo-Guerrero, M., Cardona, P., Castellanos, M., de Torres-Chacón, R., Gil-Núñez, A., Guillán, M., Martínez-Sánchez, P., Palacio-Portilla, E. J., Purroy, F. F., Segura, T., et al. (2026) · Neurología (English Edition) · doi:10.1016/j.nrleng.2026.502076
Wang, X., & Tu, X. (2026) · Vessel Plus · doi:10.20517/2574-1209.2025.153
Gnanapradeepan, K., Manska, S., Schwartz, B., Golczer, G., Huang, J., Kelkar, R. S., Masteller, A. M., Pilankar, S., Richter, M., Waldron, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.02.729508
Effects of inclisiran therapy on metabolomic and lipoproteomic profiles in dyslipidemic patients
Patrussi, J., Vignoli, A., Tenori, L., Sorrentino, A., Berteotti, M., Lotti, E., Crudele, F., Taranta, G. C., Rogolino, A. A., Barbieri, G., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1824522
Martin, A., García, H. M., Bañares, I., Khatib, A., & Badiola, I. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105429
Inclisiran—will it fulfill its promise?
Zadeh, S. S. T., Fogacci, F., & Hadaegh, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104848
Recio-López, P., Rehues, P., Berggren, P., Juntti‐Berggren, L., & Valladolid‐Acebes, I. (2026) · Biomedicines · doi:10.3390/biomedicines14071481
Hou, X., Gao, X., Wang, S., Wang, S., Cui, W., Ng, J. Y. A., Wang, S., Wang, B., Shen, Y., Yang, Q., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115159
Niazi, S. K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080941
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
Schöttler, A. K., Mané-Damas, M., Arets, B., Peng, S., Molenaar, P. C., Baets, M. H. D., Claessen, S. M. H., Barbour, T., Richardson, E., Eyerman, D. J., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08832-5
Photocatalytic synthesis of phosphorothioates by sulfur transfer from thiosulfate
Budeev, A., Bon, C., & Sparr, C. (2026) · Chemical Science · doi:10.1039/d6sc06072b
Personne, H., Kreutter, D., & Gunasekera, K. (2026) · Receptors · doi:10.3390/receptors5040033
Buchwald, J. E., Tocheny, C. E., Kharroubi, H., Tfayli, B., Sanatkar, A., Taeye, S. D., Ross, V. M., Michaud, W. A., Fakih, H. H., Osho, A. A., et al. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.10.003
Molecular basis for developing tumor-targeted siRNAs for future immunotherapy
Sioud, M. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2748740
Zhang, E., Zheng, W., LI, Y., Cheng, Z., Cai, Y., Cheng, Y., Zhang, X., Hou, Q., Liu, Y., Bingxue, M., et al. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2721709
siRNA therapeutics: from hepatic delivery to extrahepatic targeting
Wang, N., Meng, L., Shi, J.-X., & Bartneck, M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2754564
BindingDB (2021) · UC San Diego · doi:10.7270/q2j38wzz
BindingDB (2024) · UC San Diego · doi:10.7270/q25x2f5v
Metadata
- Authors
- Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., Fernando, C., Kauffman, R. S., Kallend, D., Vaishnaw, A., & Simon, A.
- Affiliations
- Alnylam Pharmaceuticals (United States) (US)
- St George's, University of London (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-05
- Volume
- 376
- Issue
- 1
- Pages
- 41-51
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5778873
- OpenAlex
- W2555483953
- Cited by
- 768
- References
- 29
- Citations by year
- 2026: 43 · 2025: 61 · 2024: 84 · 2023: 89 · 2022: 85 · 2021: 68 · 2020: 88 · 2019: 76 · 2018: 95 · 2017: 74
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL020948)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, PCSK9 inhibition, RNA interference therapy, LDL cholesterol lowering, hypercholesterolemia, statin therapy, pharmacokinetics, pharmacodynamics, safety, multiple-dose regimen, single ascending dose, healthy volunteers, lipid-lowering drugs, hypertriglyceridemia, hyperuricemia
- MeSH terms
- RNAi Therapeutics, Proprotein Convertase 9, PCSK9 Inhibitors, Acetylgalactosamine, Adolescent, Adult, Aged, Anticholesteremic Agents, Female, Humans, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Single-Blind Method, RNA, Small Interfering, RNA-Induced Silencing Complex, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
